

Korean startup Lunit collaborates with Society for Immunotherapy of Cancer

04 February 2025 | News

To enhance immunotherapy research conducted by leading experts in oncology, pathology, and immunology



Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and therapeutics, has entered into a partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration will launch the "Lunit Research Programme" for SITC members, granting access to Lunit SCOPE IO for quantitative immune phenotyping and tumour microenvironment (TME) analysis from H&E (Hematoxylin and eosin stain) whole slide images (WSIs).

SITC is the world's leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Through this programme, Lunit and SITC will support academic and non-profit researchers who are SITC members by offering use of Lunit's AI model, Lunit SCOPE IO, at no cost.

The programme will enable participants to conduct advanced analyses of histologic features from H&E whole slides images, including cell identification such as Tumour-Infiltrating Lymphocytes (TILs), macrophages, endothelial cells, and more; tissue segmentation; and quantitative immune phenotyping (e.g. inflamed, excluded, and desert), providing valuable insights for biomarker discovery and immunotherapy research.

Lunit SCOPE IO is an AI solution developed to quantify histology from H&E WSIs, bridging the gap between pathology and precision oncology. Its advanced capabilities provide researchers with insights into the immune landscape of tumors, enabling the identification of biomarkers predictive of immunotherapy response. This innovative approach supports the discovery of novel treatment strategies and enhances cancer immunotherapy research.